Evidence map›Paper›PMID 25092141›Full record

ArticleLeukemia2015

Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study.

L S G Østgård, J M Nørgaard, H Sengeløv, M Severinsen, L S Friis, C W Marcher, I H Dufva, M Nørgaard

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

L S G Østgård1] Department of Hematology, Aarhus University Hospital, Aarhus, Denmark [2] Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
J M NørgaardDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
H SengeløvDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
M Severinsen1] Department of Hematology, Aalborg University Hospital, Aalborg, Denmark [2] Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
L S FriisDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
C W MarcherDepartment of Hematology, Odense University Hospital, Odense, Denmark.
I H DufvaDepartment of Hematology, Herlev University Hospital, Herlev, Denmark.
M NørgaardDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the world population ages, the comorbidity burden in acute myeloid leukemia (AML) patients increases. Evidence on how to integrate comorbidity measures into clinical decision-making is sparse. We determined the prognostic impact of comorbidity and World Health Organization Performance Status (PS) on achievement of complete remission and mortality in all Danish AML patients treated between 2000 and 2012 overall and stratified by age. Comorbidity was measured using a modified version of the Charlson Comorbidity Index, with separate adjustment for pre-leukemic conditions. Of 2792 patients, 1467 (52.5%) were allocated to intensive therapy. Of these patients, 76% did not have any comorbidities, 19% had one comorbid disease and 6% had two or more comorbidities. Low complete remission rates were associated with poor PS but not with comorbidity. Surprisingly, among all intensive therapy patients, presence of comorbidity was not associated with an increased short-term mortality (adjusted 90 day mortality rate (MR)=1.06 (95% confidence interval (CI)=0.76-1.48)) and, if any, only a slight increase in long-term mortality (91 day-3 year adjusted MR=1.18 (95%CI=0.97-1.44). Poor PS was strongly associated with an increased short- and long-term mortality (adjusted 90 day MR, PS⩾2=3.43 (95%CI=2.30-5.13); adjusted 91 day-3 year MR=1.35 (95%CI=1.06-1.74)). We propose that more patients with comorbidity may benefit from intensive chemotherapy.

Indexed as

RegistriesAdolescentAdultAgedAged, 80 and overAge FactorsAntineoplastic AgentsCardiovascular DiseasesCohort StudiesComorbidityDenmarkFemaleHumansLeukemia, Myeloid, AcuteLung DiseasesMaleAntineoplastic Agents

Identifiers

PMID25092141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.